James Sabry at #JPM24 (Brian Benton Photography)
May 28, 2024 04:09 AM EDTUpdated 06:08 AM
People
Bioregnum

Af­ter 14 years call­ing part­ner­ing shots at Genen­tech/Roche, James Sabry is head­ed back in­to the biotech fray

James Sabry, the long­time doyen of biotech deal­mak­ers from his glob­al perch at Roche/Genen­tech, is jump­ing to the US biotech scene.

The Basel-based phar­ma gi­ant …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times